|
PZ-128
|
DB11839 |
[PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.] |
|
String bean
|
DB10508 |
[String bean allergenic extract is used in allergenic testing.] |
|
3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE
|
DB08204 |
|
|
Titanium dioxide
|
DB09536 |
[Titanium dioxide, also known as titanium(IV) oxide or titania, is the naturally occurring oxide of titanium. It is used as a pigment under the names titanium white, Pigment White 6 (PW6), or CI 77891. It is typically extracted from ilmenite, rutile and anatase.] |
|
Coffee bean
|
DB10525 |
[Coffee bean allergenic extract is used in allergenic testing.] |
|
Ligelizumab
|
DB11856 |
[Ligelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.] |
|
Octocrylene
|
DB09535 |
[Octocrylene is an organic compound used as an ingredient in sunscreens and cosmetics.] |
|
Revefenacin
|
DB11855 |
[Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LABA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LABA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD).[A40025] From the LABA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]] |
|
4-(1,3-BENZOXAZOL-2-YL)-2,6-DIMETHYLPHENOL
|
DB08205 |
|
|
Coconut
|
DB10523 |
[Coconut allergenic extract is used in allergenic testing.] |
|
Astodrimer
|
DB11854 |
[Astodrimer has been used in trials studying the treatment and prevention of Bacterial Vaginosis. It is a lysine-based dendrimer with naphthalene disulfonic acid surface groups.] |
|
4-(1,3-BENZOXAZOL-2-YL)-2,6-DIBROMOPHENOL
|
DB08206 |
|
|
Iodine povacrylex
|
DB09537 |
[Iodine povacrylex (DuraPrep) is a surgical solution, film-forming iodophor complex that provides fast acting, persistent, broad-spectrum antimicrobial activity. DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria
that can potentially cause skin infection.
It is a broad spectrum antiseptic and can provide almost 99.9% antiseptic conditions.
It is intended for local use only. Prolonged skin exposure could cause skin defatting manifested by the following signs/symptoms; localized redness, itching, drying and cracking of skin.] |
|
Relugolix
|
DB11853 |
[Relugolix has been used in trials studying the treatment of Endometriosis, Prostate Cancer, Uterine Fibroids, and Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.] |
|
2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE
|
DB08207 |
|
|
Egg
|
DB10529 |
[Egg allergenic extract is used in allergenic testing.] |
|
2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
|
DB08208 |
|
|
Omega-3-acid ethyl esters
|
DB09539 |
[Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia[FDA Label][A176687]. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849].] |
|
Egg white
|
DB10528 |
[Egg white allergenic extract is used in allergenic testing.] |
|
Brexanolone
|
DB11859 |
[As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females [F4066]. Since PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening condition [F4072]. Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083]. The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066].
In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) in postpartum women susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not mediate activities directly associated with PPD like natural fluctuations in the levels of endogenous neuroactive steroids like allopregnanolone [F4063].
And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare success in the weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone vs. placebo when added to standard-of-care [L5750].] |
